G1 Therapeutics ( (GTHX) ) just unveiled an update.
Pharmacosmos A/S has finalized its acquisition of G1 Therapeutics at $7.15 per share, with the tender offer successfully closing at a total equity value of approximately $405 million. This strategic move enhances Pharmacosmos’s growth and product portfolio, including the innovative cancer therapy COSELA®. Following the merger, G1 Therapeutics will no longer be listed on NASDAQ, becoming a wholly owned subsidiary of Pharmacosmos. The combined efforts of the two companies aim to extend COSELA®’s reach to benefit more cancer patients globally.
For detailed information about GTHX stock, go to TipRanks’ Stock Analysis page.
